GlassScriptPhysician profile
Benjamin L Shipton
NPI 1912980723
$438.22
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $119.66 | 2019-2020 | |
| Novo Nordisk INC | $95.01 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.43 | 2019 | |
| Amgen INC. | $24.02 | 2019 | |
| Pfizer INC. | $23.45 | 2019 | |
| Astellas Pharma US INC | $20.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.20 | 2019 | |
| Allergan, INC. | $14.13 | 2019 | |
| Strongbridge US INC. | $13.92 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2019 | |
| Genentech USA, INC. | $13.50 | 2020 | |
| Amarin Pharma, INC. | $13.35 | 2019 | |
| Merck Sharp & Dohme LLC | $12.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Shipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.